BDX Becton Dickinson
FY2025 10-K
Becton Dickinson (BDX) filed its fiscal year 2025 10-K annual report with the SEC on Nov 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and marketing of medical devices with focus on patient and medication delivery solutions
- • New emphasis: Remediation and U.S. market return of BD Alaris™ Infusion System post FDA 510(k) clearance July 2023
Management Discussion & Analysis
- • Total revenue $23.5B, up 6% YoY driven by Medical segment growth
- • Operating margin 18.9%, down from 20.3% YoY due to higher input costs
Risk Factors
- • FDA Consent Decree on U.S. infusion pump business, risk of manufacturing suspension and significant monetary damages if violated
- • Geopolitical exposure to ongoing conflicts in Ukraine, Middle East, and Asia impacting international operations and supply chains
Financial SummaryXBRL
Revenue
$21.8B
Net Income
$1.7B
Operating Margin
11.8%
Net Margin
7.7%
ROE
6.6%
Total Assets
$55.3B
EPS (Diluted)
$5.82
Operating Cash Flow
$3.4B
Source: XBRL data from Becton Dickinson FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Becton Dickinson
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.